drugset / Trial / NCT02905942
PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to evaluate the efficacy and safety of PEG-rhG-CSF on the recovery of hematopoietic function after autologous stem cell transplantation in patients with lymphoma.
Timeline
- Start
- 2015-12
- Primary completion
- 2018-12
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegfilgrastim | Protein / enzyme biologic | 100 ug/kg | — |
| Subject | Pegfilgrastim | Protein / enzyme biologic | 6 mg | — |
| Comparator | filgrastim | Protein / enzyme biologic | 5 ug/kg | — |